Literature DB >> 31872914

PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Yiliao Luo1,2,3, Mengxing Li1,4, Uday P Pratap1, Suryavathi Viswanadhapalli1, Junhao Liu1,5, Prabhakar P Venkata1, Kristin A Altwegg1,6, Bridgitte E Palacios1, Xiaonan Li1, Yihong Chen1,7, Manjeet K Rao6,8, Andrew J Brenner6,9, Gangadhara R Sareddy1,6, Ratna K Vadlamudi1,6.   

Abstract

Medulloblastoma (MB) is the most common and deadliest brain tumor in children. Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a scaffolding protein and its oncogenic signaling is implicated in the progression of several cancers. However, the role of PELP1 in the progression of MB remains unknown. The objective of this study is to examine the role of PELP1 in the progression of MB. Immunohistochemical analysis of MB tissue microarrays revealed that PELP1 is overexpressed in the MB specimens compared to normal brain. Knockdown of PELP1 reduced cell proliferation, cell survival, and cell invasion of MB cell lines. The RNA-sequencing analysis revealed that PELP1 knockdown significantly downregulated the pathways related to inflammation and extracellular matrix. Gene set enrichment analysis confirmed that the PELP1-regulated genes were negatively correlated with nuclear factor-κB (NF-κB), extracellular matrix, and angiogenesis gene sets. Interestingly, PELP1 knockdown reduced the expression of NF-κB target genes, NF-κB reporter activity, and inhibited the nuclear translocation of p65. Importantly, the knockdown of PELP1 significantly reduced in vivo MB progression in orthotopic models and improved the overall mice survival. Collectively, these results suggest that PELP1 could be a novel target for therapeutic intervention in MB.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NF-κB; PELP1; coactivator; medulloblastoma; oncogene

Mesh:

Substances:

Year:  2019        PMID: 31872914      PMCID: PMC7021561          DOI: 10.1002/mc.23152

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  44 in total

Review 1.  Cancer secretome and inflammation: The bright and the dark sides of NF-κB.

Authors:  Daria Capece; Daniela Verzella; Alessandra Tessitore; Edoardo Alesse; Carlo Capalbo; Francesca Zazzeroni
Journal:  Semin Cell Dev Biol       Date:  2017-08-02       Impact factor: 7.727

2.  Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Authors:  Lin Yang; Preethi Ravindranathan; Meera Ramanan; Payal Kapur; Stephen R Hammes; Jer-Tsong Hsieh; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2012-03-08

Review 3.  Medulloblastoma.

Authors:  Paul A Northcott; Giles W Robinson; Christian P Kratz; Donald J Mabbott; Scott L Pomeroy; Steven C Clifford; Stefan Rutkowski; David W Ellison; David Malkin; Michael D Taylor; Amar Gajjar; Stefan M Pfister
Journal:  Nat Rev Dis Primers       Date:  2019-02-14       Impact factor: 52.329

4.  Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.

Authors:  Brian J Girard; Todd P Knutson; Bethanie Kuker; Laura McDowell; Kathryn L Schwertfeger; Julie H Ostrander
Journal:  J Biol Chem       Date:  2016-11-23       Impact factor: 5.157

5.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

Review 6.  Medulloblastoma: From Myth to Molecular.

Authors:  Vijay Ramaswamy; Michael D Taylor
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

Review 7.  PELP1: Structure, biological function and clinical significance.

Authors:  Gangadhara Reddy Sareddy; Ratna K Vadlamudi
Journal:  Gene       Date:  2016-03-18       Impact factor: 3.688

8.  Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells.

Authors:  Sujit S Nair; Sandip K Mishra; Zhibo Yang; Seetharaman Balasenthil; Rakesh Kumar; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 9.  Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies.

Authors:  Jun Wang; Alexandra Garancher; Vijay Ramaswamy; Robert J Wechsler-Reya
Journal:  Annu Rev Neurosci       Date:  2018-04-11       Impact factor: 12.449

10.  Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.

Authors:  Susan E Spiller; Naomi J Logsdon; Lindsey A Deckard; Harald Sontheimer
Journal:  BMC Cancer       Date:  2011-04-14       Impact factor: 4.430

View more
  6 in total

Review 1.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

2.  Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.

Authors:  Junhao Liu; Zexuan Liu; Mengxing Li; Weiwei Tang; Uday P Pratap; Yiliao Luo; Kristin A Altwegg; Xiaonan Li; Yi Zou; Hong Zhu; Gangadhara R Sareddy; Suryavathi Viswanadhapalli; Ratna K Vadlamudi
Journal:  Mol Oncol       Date:  2021-02-09       Impact factor: 6.603

3.  Cromolyn platform suppresses fibrosis and inflammation, promotes microglial phagocytosis and neurite outgrowth.

Authors:  Yi-Jun Wang; Matthew A Downey; Sungwoon Choi; Timothy M Shoup; David R Elmaleh
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

4.  Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC.

Authors:  Zexuan Liu; Kristin A Altwegg; Junhao Liu; Susan T Weintraub; Yidong Chen; Zhao Lai; Gangadhara R Sareddy; Suryavathi Viswanadhapalli; Ratna K Vadlamudi
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.575

5.  Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer.

Authors:  Jianlin Zhu; Lu Wang; Fan Liu; Jinghua Pan; Zhimeng Yao; Yusheng Lin; Yabing Yang; Xiao Xiong; Kai Li; Yi Yang; Yiran Zhang; Xiaodong Chu; Yunlong Pan; Hao Zhang
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

Review 6.  Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.

Authors:  Sheng-Kai Hsu; Chia-Yang Li; I-Ling Lin; Wun-Jyun Syue; Yih-Fung Chen; Kai-Chun Cheng; Yen-Ni Teng; Yi-Hsiung Lin; Chia-Hung Yen; Chien-Chih Chiu
Journal:  Theranostics       Date:  2021-08-12       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.